Silence Therapeutics (SLN) Shares Rise +20% on Clinical Wins and Capital Raise
Key Takeaways
- Silence Therapeutics shares rose roughly 20% over the 30-day period, driven by positive clinical data and a major capital raise.
- The biggest catalyst was positive Phase 2 topline results for divesiran in polycythemia vera, which sent the stock up about 29% in a single session to a 52-week high.
- Investors also digested a narrower quarterly net loss, an upsized public offering, and encouraging data for zerlasiran in high lipoprotein(a).
- The stock has more than doubled over the trailing quarter, reflecting a broad re-rating of the company's siRNA pipeline.
Understanding Silence Therapeutics (SLN) and Its Position in siRNA Therapies
SLN is a UK-headquartered, clinical-stage biotechnology company focused on short interfering RNA (siRNA) therapies, which are designed to silence disease-causing genes. The company leverages its proprietary mRNAi GOLD platform to engineer medicines that target the liver and address conditions with high unmet medical need across cardiovascular disease, hematology, and rare diseases.
Its two most advanced wholly owned candidates are divesiran (SLN124), in development for polycythemia vera (PV), and zerlasiran (SLN360), designed to lower lipoprotein(a), a genetic risk factor for cardiovascular disease. Silence also has an additional clinical-stage candidate being developed with partner AstraZeneca. I follow the stock closely for clinical readouts, regulatory milestones, and potential partnering activity, given the large addressable markets for its programs. In my view, checking comparable names via Tickeron’s AI Screener helps put these developments in context.
SLN Stock Performance: The Last 30 Days Compared to the Quarter
Over the trailing 30 days, Silence Therapeutics shares advanced approximately 20%, climbing from around $11 per American Depositary Share (ADS) in late July to roughly $13.27 in late August. The move was concentrated in a sharp rally in early August, when the stock surged nearly 30% in a single session and reached a 52-week intraday high of $17.58 before settling back as the market absorbed a follow-on offering.
The picture is even stronger over the trailing quarter. From roughly $6.50 in early June, the stock has more than doubled, exceeding $13 in late August. This multi-month appreciation reflects a sustained re-rating of the company's pipeline rather than a one-day event, with momentum building through a series of positive clinical updates and a successfully completed capital raise. From what I see, the pattern holds up when I review it against Tickeron’s AI Trend Prediction Engine signals.
Key Drivers Behind the Recent 30-Day Move
The dominant catalyst was the positive Phase 2 SANRECO topline data for divesiran in polycythemia vera, announced in early August. In the 36-week, randomized, double-blind, placebo-controlled portion of the trial, patients across two dosing groups met the primary endpoint with response rates of 93% and 81%, respectively, alongside reduced phlebotomy dependency and a consistent safety profile. The results were interpreted by investors as supporting a potentially best-in-class profile.
The same period also brought second-quarter results, with the net loss narrowing to $12 million from approximately $27 million a year earlier. Concurrently, the company announced a proposed public offering of ADSs, which was later upsized and closed with the full exercise of the underwriters' option for total gross proceeds of roughly $201.3 million. Positive 36-week data from the ALPACAR-360 Phase 2 study of zerlasiran, showing median Lp(a) reductions of 90% or greater, added further support to sentiment.
What Powered the Stronger Quarterly Performance
The quarterly rally was built on accumulating clinical validation across Silence's two lead programs. Positive zerlasiran data in elevated Lp(a) reinforced the cardiovascular opportunity, while progress toward a Phase 3 study and ongoing partnering discussions shaped the broader narrative. The company also signaled that it would advance the zerlasiran Phase 3 outcomes trial once a partner is secured, a decision aimed at managing development costs and extending the cash runway.
In hematology, the divesiran program transitioned from earlier proof-of-concept signals to a successful Phase 2 readout, materially de-risking the asset in the eyes of the market. The successful upsized financing during the quarter strengthened the balance sheet and removed a near-term overhang, even as it introduced share dilution. Collectively, these developments supported a sustained repricing of the stock across the quarter.
Forward-Looking Factors for SLN Investors
Investors will be watching several forward-looking factors. For divesiran, attention turns to a planned Phase 3 trial in polycythemia vera and any additional durability or safety data from the SANRECO program. For zerlasiran, the key variable is whether Silence secures a development partner for the Phase 3 outcomes study, which would shape both the timeline and the company's funding requirements.
Other considerations include further quarterly financial updates, cash runway guidance following the recent offering, and progress in the collaboration with AstraZeneca. Regulatory developments and competitive dynamics in the Lp(a) and PV markets will also influence sentiment. As with all clinical-stage biotechnology companies, binary trial outcomes, financing decisions, and broader market conditions remain significant risks, and no specific investment outcome should be assumed.
Using Tickeron AI Trading Bots for Biotech Monitoring
In my own process, I sometimes review Tickeron’s AI Trading Bots to see how automated strategies are handling names like SLN during periods of clinical volatility. The platform offers a range of bots with different timeframes and risk parameters, which can complement traditional fundamental work without replacing it. This has been a helpful way for me to cross-check momentum signals alongside the latest trial readouts and financing news.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
SLN in -6.60% downward trend, declining for three consecutive days on August 20, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLN declined for three days, in of 310 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SLN moved out of overbought territory on August 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for SLN turned negative on August 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
SLN broke above its upper Bollinger Band on August 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on SLN as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLN advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 192 cases where SLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.459) is normal, around the industry mean (20.143). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (444.692).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement